
- A meta-analysis discovered that one sort of GLP-1 treatment could also be simpler than others.
- The evaluation confirmed that GLP-1s containing tirzepatide (Zepbound, Mounjaro) helped folks lose extra weight than these containing semaglutide (Ozempic, Wegovy).
- Liraglutide (Saxenda) had the bottom weight reduction proportion amongst customers.
- The success of tirzepatide could also be resulting from its twin mechanism, which targets a number of receptors.
As round
A latest
“We have been inquisitive about discovering which drug provides essentially the most weight reduction and doesn’t have increased charges of negative effects like nausea and gastrointestinal issues,” Pooja Gokhale, corresponding creator of the evaluate and a doctoral pupil within the College of Georgia School of Pharmacy, mentioned in a press release.
“Tirzepatide appears to be the higher choice,” Gokhale mentioned.
The evaluation discovered that these utilizing tirzepatide (Zepbound or Mounjaro) misplaced 15–20% of their physique weight.
By comparability, members taking semaglutide (Ozempic or Wegovy) misplaced round 12–13% of their physique weight. Liraglutide (Saxenda) confirmed the bottom weight reduction proportion, round 5%.
GLP-1 medications work by mimicking pure hormones within the intestine, which assist to decrease blood sugar, gradual digestion, and promote emotions of fullness to assist weight reduction.
Semaglutide and liraglutide goal GLP-1 receptors, whereas tirzepatide targets each GLP-1 receptors and one other intestine hormone, GIP. This twin mechanism could also be what’s driving better weight reduction outcomes with tirzepatide.
The researchers additionally counsel that the way in which the physique processes and interacts with the treatment might play a job in weight reduction.
Liraglutide, particularly, has a half-life of solely round 13 hours and requires a every day injection. Semaglutide and tirzepatide have half-lives of 1 week and 5 days, respectively, permitting weekly injections.
“Whereas tirzepatide might obtain better common weight reduction, there isn’t any single ‘finest’ treatment for each affected person,” mentioned Clare Thompson, a common practitioner and weight administration providers lead at Cadogan Clinic in the UK. Thompson wasn’t concerned within the examine.
“Future analysis will assist us higher perceive whether or not the extra weight reduction seen with tirzepatide interprets into superior long-term well being advantages in contrast with different GLP-1 therapies.”
Whereas tirzepatide might result in better weight reduction, a semaglutide treatment could also be extra appropriate for some folks.
Semaglutide is commonly cheaper than tirzepatide, which can be a deciding issue.
“Semaglutide has been available on the market for longer and subsequently has extra sturdy, long-term knowledge on outcomes for lowering heart attacks and strokes, and likewise good proof to help a discount in renal disease,” mentioned Thompson.
Semaglutide can be out there as an oral pill, which can assist those that are averse to injections.
Oral semaglutide (Rybelsus) was the primary oral GLP-1 approved by the Meals and Drug Administration (FDA). It was initially permitted to deal with sort 2 diabetes, however may assist weight reduction. In December 2025, the FDA also approved an oral form of Wegovy particularly for weight reduction.
Regardless of the widespread success of GLP-1s for weight reduction, specialists encourage wholesome way of life habits, resembling a balanced weight-reduction plan and common train.
“Weight problems needs to be seen as a power medical situation requiring a customized therapy strategy — there isn’t a one-size-fits-all,” mentioned Thompson.
“One of the best outcomes happen when pharmacological therapy is mixed with sustainable way of life modifications, together with improved diet, common bodily exercise, satisfactory protein consumption, and resistance coaching to assist protect muscle mass throughout weight reduction.”




:max_bytes(150000):strip_icc()/HDC-GettyImages-668641904-9179dc9fe60446d8b4d8a08fbffcf46d.jpg?w=600&resize=600,400&ssl=1)





Recent Comments